Home/Filings/4/0001104659-25-010610
4//SEC Filing

Lee Jennifer Kayden 4

Accession 0001104659-25-010610

CIK 0001649904other

Filed

Feb 6, 7:00 PM ET

Accepted

Feb 7, 5:05 PM ET

Size

9.2 KB

Accession

0001104659-25-010610

Insider Transaction Report

Form 4
Period: 2025-02-05
Lee Jennifer Kayden
EVP, Head of North America
Transactions
  • Sale

    Common Stock

    2025-02-05$60.08/sh1,733$104,1212,305 total
  • Sale

    Common Stock

    2025-02-05$61.95/sh200$12,390972 total
  • Sale

    Common Stock

    2025-02-05$61.01/sh1,133$69,1301,172 total
Footnotes (3)
  • [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $59.54 to $60.43. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $60.67 to $61.49. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Issuer

RHYTHM PHARMACEUTICALS, INC.

CIK 0001649904

Entity typeother

Related Parties

1
  • filerCIK 0001801372

Filing Metadata

Form type
4
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 5:05 PM ET
Size
9.2 KB